Apple Inc. is preparing to release iOS 26.4, a software update that promises to meaningfully expand the health-monitoring capabilities of the Apple Watch and iPhone ecosystem. Among the headline features: a new “Average Bedtime Vitals” dashboard, the restoration of blood oxygen monitoring for U.S. customers, and a suite of refinements that signal the company’s intensifying focus on preventive health technology. For an industry already watching Apple’s every move in digital health, the update represents the clearest evidence yet that Cupertino views clinical-grade wellness data as a core pillar of its hardware and services strategy.
The details of the forthcoming update were first reported by MacRumors, which obtained information from developer beta builds seeded to testers in mid-February 2026. According to the report, iOS 26.4 will ship alongside watchOS 13.4 and is expected to reach the general public in the spring.
Average Bedtime Vitals: Turning Nightly Data Into Longitudinal Trends
Perhaps the most substantive new feature in iOS 26.4 is the introduction of “Average Bedtime Vitals,” a tool that aggregates nightly health readings—heart rate, respiratory rate, blood oxygen saturation, and wrist temperature—into rolling averages viewable over seven-day, 30-day, and 90-day windows. The feature builds on the existing Vitals app introduced in watchOS 11, which already surfaces nightly health metrics each morning but presents them largely as isolated snapshots.
The shift from single-night readings to averaged trend lines may sound incremental, but clinicians and health-tech analysts say it addresses one of the most persistent criticisms of consumer wearable data: noise. A single night’s heart rate reading can be skewed by alcohol consumption, a late workout, ambient temperature, or even the position of the watch on the wrist. Averaged over weeks or months, however, those readings begin to approximate the kind of baseline data that physicians use to flag early signs of atrial fibrillation, sleep apnea, respiratory illness, or metabolic dysfunction.
Why Trend Data Matters More Than Any Single Reading
Apple has been moving in this direction for several years. The company’s Research app has long collected longitudinal data for its heart and movement studies conducted in partnership with institutions such as the University of Michigan and Brigham and Women’s Hospital. But those datasets have historically been siloed inside research frameworks, unavailable to everyday users in a digestible format. With Average Bedtime Vitals, Apple appears to be democratizing that longitudinal view, packaging it inside the Health app where users already check their daily step counts and sleep duration.
Industry observers note that the timing is significant. Competitors including Google’s Fitbit division, Samsung, and Garmin have all invested heavily in sleep-health analytics over the past 18 months. Google’s Pixel Watch 3, released in late 2025, already offers a “Sleep Score” trend graph that tracks week-over-week changes. Samsung’s Galaxy Watch Ultra 2 provides a similar rolling-average view of overnight heart rate variability. Apple’s new feature closes a gap that had begun to widen, particularly among health-conscious consumers who compare platforms before committing to an ecosystem.
Blood Oxygen Returns to U.S. Apple Watches After Patent Dispute Resolution
The second major development in iOS 26.4 is the full restoration of blood oxygen (SpO2) monitoring on Apple Watch models sold in the United States. As MacRumors detailed, the feature had been disabled on devices sold domestically since late 2023, when Apple lost a patent infringement case brought by medical device maker Masimo Corporation. The International Trade Commission issued an import ban on Apple Watch models containing the disputed pulse oximetry technology, forcing Apple to ship watches without the feature enabled in the U.S. market.
Apple and Masimo reached a licensing agreement in late 2025 after protracted negotiations, clearing the legal pathway for SpO2 to return. iOS 26.4 and the accompanying watchOS 13.4 update will re-enable the sensor on compatible hardware, including the Apple Watch Series 10, Apple Watch Ultra 3, and retroactively on the Series 9 and Ultra 2 models that had shipped with the feature turned off. For millions of U.S. Apple Watch owners, the update will unlock functionality that their international counterparts have enjoyed without interruption.
The Masimo Saga and Its Implications for Wearable IP
The Masimo dispute has been one of the most closely watched intellectual-property battles in the consumer electronics industry. Masimo, a medical technology company based in Irvine, California, accused Apple of poaching its engineers and incorporating proprietary pulse oximetry algorithms into the Apple Watch without authorization. Apple denied the allegations and fought the import ban through multiple appeals, but ultimately chose to negotiate a license rather than continue selling watches with a key health sensor disabled.
The resolution carries broader implications. It establishes a precedent that even the world’s most valuable company cannot simply absorb patented medical-device technology into a consumer product without consequence. For smaller health-tech firms developing novel biosensors—companies working on non-invasive glucose monitoring, hydration tracking, or continuous blood pressure measurement—the outcome offers a measure of reassurance that their intellectual property will be respected as Big Tech moves deeper into clinical health.
Refinements to Sleep Apnea Detection and Respiratory Health
Beyond the headline features, iOS 26.4 includes several under-the-radar improvements to Apple’s respiratory health toolkit. According to the MacRumors report, the update refines the sleep apnea notification algorithm that Apple introduced with the Apple Watch Series 10 and watchOS 11. The updated algorithm reportedly reduces false-positive alerts—a common complaint among early adopters—by incorporating the new averaged vitals data into its risk assessment model.
The sleep apnea feature, which received FDA clearance as a De Novo medical device in 2024, was groundbreaking in that it brought a screening tool for a condition affecting an estimated 30 million Americans to a device already on millions of wrists. But its clinical utility has been limited by a relatively high rate of notifications that, upon follow-up with a physician, turned out to be benign. By weighting trend data more heavily than single-night anomalies, the refined algorithm aims to improve the positive predictive value of its alerts—a metric that matters enormously to both patients and the physicians who receive their concerned phone calls.
Apple’s Health Ambitions in a Regulatory Tightrope
Apple’s expanding health feature set raises ongoing questions about regulatory oversight. The company has secured FDA clearances for its electrocardiogram (ECG) app, irregular rhythm notification, and sleep apnea detection, but many of its other health features—including heart rate monitoring, respiratory rate tracking, and wrist temperature sensing—operate in a gray zone that the FDA has generally chosen not to regulate as medical devices. The Average Bedtime Vitals feature, which synthesizes multiple data streams into trend analyses, sits squarely in that ambiguous territory.
Health policy experts have noted that as consumer wearables become more sophisticated, the line between “wellness” products and “medical” devices will become increasingly difficult to maintain. Apple has been careful to frame its health features in wellness-oriented language—the Vitals app tells users when readings are “atypical” rather than “abnormal,” for instance—but the practical effect of these tools is to encourage users to seek medical attention based on algorithmic assessments. Whether the FDA will eventually require premarket review for features like Average Bedtime Vitals remains an open question, one that the agency’s Digital Health Center of Excellence is actively studying.
What iOS 26.4 Signals About Apple’s Product Roadmap
For Apple, the health features in iOS 26.4 are not isolated additions but components of a long-term strategy that CEO Tim Cook has described as the company’s “greatest contribution to mankind.” Each successive watchOS release has added another layer to Apple’s health data stack: heart rate variability in 2017, ECG in 2018, blood oxygen in 2020, temperature sensing in 2022, sleep apnea detection in 2024, and now longitudinal trend analysis in 2026.
The trajectory points toward an eventual integration with electronic health record systems, insurance wellness programs, and possibly even clinical trial recruitment platforms. Apple Health Records, which allows users to import data from participating hospitals, already provides a rudimentary bridge between consumer and clinical data. Average Bedtime Vitals could strengthen that bridge by giving physicians access to weeks or months of objective, passively collected health data—information that is far more valuable than the subjective self-reports that dominate most primary care encounters today.
The Competitive Stakes for Wearable Health Technology
As Apple prepares to ship iOS 26.4, the competitive pressure in wearable health technology continues to mount. Google is reportedly developing a non-invasive continuous glucose monitor for a future Pixel Watch, a capability that would leapfrog anything currently available on the Apple Watch. Samsung has partnered with the Korean Ministry of Food and Drug Safety to explore regulatory pathways for blood pressure monitoring on the Galaxy Watch. And startups like Oura, Whoop, and Ultrahuman are carving out dedicated niches in sleep and recovery analytics, often with more granular data presentation than Apple offers.
Apple’s advantage remains its installed base—an estimated 100 million active Apple Watch users worldwide—and its tight integration between hardware, software, and services. iOS 26.4 leverages that integration to deliver features that require coordination across the watch’s sensors, the iPhone’s processing power, and the Health app’s data visualization engine. For competitors without that vertical integration, matching the seamlessness of Apple’s implementation remains a formidable challenge.
The update is expected to enter public beta testing in March 2026, with a general release anticipated in April. For the millions of Apple Watch users who have been waiting for blood oxygen monitoring to return—and for the health-tech industry watching Apple’s next moves—iOS 26.4 cannot arrive soon enough.